HER2 Support Group Forums - View Single Post - predicting complete pathological response ie,chemoworking, by molecular subtype here?

Lani · 09-20-2007, 08:44 PM

but I am disappointed in the article as many details are not addressed.

The variants of her2 eg the truncated version are genetic variants....I believe this addresses the variant of the "her2" molecular subtype ie, the grouping based on multigene array chip profiles of multitude of genes.
This study is out of William Beaumont Hospital in Michigan and the numbers of tumors studied was limited.

They did not test for many of the biomarkers I would have found interesting eg her3, phospo-her2, etc.

Dr. Charles Perou who was instrumental in naming the 5 molecular subtypes of breast cancer believes her2+ER+ breast cancers fall within the luminal B group, as do many other authors. This paper does not specify where they believe her2+ER+ tumors fall--despite two readings I have yet to find it even referred to and yet they constitute around 45% OF HER2+ breast cancers in many studies.

I will investigate further and let you know.

09-20-2007, 08:44 PM	#9
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	don't think that is what they are referring to here but I am disappointed in the article as many details are not addressed. The variants of her2 eg the truncated version are genetic variants....I believe this addresses the variant of the "her2" molecular subtype ie, the grouping based on multigene array chip profiles of multitude of genes. This study is out of William Beaumont Hospital in Michigan and the numbers of tumors studied was limited. They did not test for many of the biomarkers I would have found interesting eg her3, phospo-her2, etc. Dr. Charles Perou who was instrumental in naming the 5 molecular subtypes of breast cancer believes her2+ER+ breast cancers fall within the luminal B group, as do many other authors. This paper does not specify where they believe her2+ER+ tumors fall--despite two readings I have yet to find it even referred to and yet they constitute around 45% OF HER2+ breast cancers in many studies. I will investigate further and let you know.